A new study on European Radiology considered patients with infiltrative non-measurable HCC and demonstrated a significant relationship between post-contrast tumor attenuation and therapeutic response after sorafenib; nevertheless, no significant change in terms of survival was recorded, due to the poor prognosis of selected patients.